3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders
globalreutersSeptember 13, 20241 Mins read 
Bicara Therapeutics’ IPO raised $315 million raised for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers. Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs.
The post 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders appeared first on MedCity News.
Related Articles
Links
Hatch Waxman turns 40. FDA: Integrating RCT into routine clinical practice. Cost...
What Are the Challenges in Building a Consumer-Focused Diagnostic Testing Startup?
During a panel discussion at the MedCity News INVEST Digital Health Conference,...
BREAKING: FG Moves To Decriminalise Suicide Attempts
FG has moved to decriminalise suicide attempts. NewsOnline Nigeria reports that...
New XEC Covid variant: What are the symptoms and is it spreading in the UK?
The Covid-19 pandemic is constantly changing, with new variants appearing occasionally. Lately,...
Leave a comment